Document:

Exhibit 10.1 - Mining Claim.

Exhibit 10.1

	[British Columbia
	Government Logo]
		  
		Mineral Titles Online Viewer
		  
		Public Access
		  
		Tenure Detail
		  
		Tenure Number ID  	516362 	View Tenure  	  
		Tenure Type  	Mineral (M) 	  	  
		Tenure Sub Type  	Claim (C) 	  	  
		Title Type	Mineral Cell Title Submission (MCX)  	  
		Mining Division  	  	  	  
		Good To Date  	2008/dec/25 	  	  
		Issue Date	2005/jul/08 	  	  
		Termination Type  	  	  	  
		Termination Comments  	  	  	  
		Termination Date  	  	  	  
		Tag Number  	  	  	  
		Claim Number  	  	  	  
		Old Tenure Code  	  	  	  
		Area in Hectares  	196.718 	  	  
		  
		Map Numbers:
		  	093A
		  
		Owners:
		  	202445 WOODBURN HOLDINGS LTD. 100.0%
		  
		Tenure Events:
		Submitter	Event 	Date 
		116548	MACPHERSON, FRANCES

JEAN  	CONV Claim Conversion (4039915)	2005/JUL/08
		116548	MACPHERSON, FRANCES

JEAN  	BSLI Transfer of Ownership  

(Bill of Sale Initiation)(4072253)  	2006/FEB/27
		116548	MACPHERSON, FRANCES

JEAN  	BSLC Transfer of Ownership  

(Bill of Sale Completion)(4072254)  	2006/FEB/27
		116548	MACPHERSON, FRANCES

JEAN  	SOW Exploration and Development Work / Expiry 

Date Change(4096303)  	2006/AUG/03

		116548	MACPHERSON,

FRANCES

JEAN  	SOW Exploration and Development Work / Expiry

Date Change(4117263)  	2006/DEC/22exhibit101.htm

    Exhibit
      10.1

     

    CONTRACT
      MANUFACTURING AGREEMENT

     

    The
      undersigned,

    

    Medtech
      Products Inc., a
company organized and existing under the laws of the State
      of Delaware, USA, having its principal place of business at 90 North Broadway,
      Irvington, New York 10533, together with any affiliate thereof, hereinafter
      called “Medtech”;

     

    And

     

    PHARMASPRAY
      B.V., a
      company organised and existing under the laws of the Netherlands, having its
      domicile at Demeterlaan 30 (9641 ML) Veendam, hereinafter called “Pharmaspray”.

     

    Sometimes
      hereinafter
      jointly referred to as the “Parties”
      or separately as the “Party”.

     

    WHEREAS:

    

    
      	
              A.  

            	
              Medtech,
                having
                acquired all of the capital stock of Wartner USA B.V., is the owner
                of all
                Intellectual Property Rights relating to the Product (as defined
                in Clause
                1) for the USA and Canada and
                is to be considered the Specification Holder of the
                Product;

            

    

    

    
      	
              B.  

            	
              Pharmaspray
                is an
                aerosol manufacturer filling aerosol cans with cosmetic and medical
                products;

            

    

    

    
      	
              C.  

            	
              The
                Products sold by
                Medtech are subject to ISO-13485 Standard and GMP 820
                standard;

            

    

    

    
      	
              D.  

            	
              Pharmaspray
                operates
                in accordance with ISO-9001:2000
                Standard;

            

    

    

    
      	
              E.  

            	
              The
                Parties wish to
                (co)operate in accordance with ISO-13485 Standard, ISO-9001:2000
                Standard,
                the Quality Manual (as defined in Clause 1) and the instructions
                of
                Medtech as specified in the Schedule(s) which form part of this
                Agreement;

            

    

    

    
      	
              F.  

            	
              The
                Parties now wish
                to formalize this Agreement as a “Turn-Key Agreement” in which they will
                include all their agreements with respect to the Procurement Services,
                Production Services, Packaging Services, Logistic Services and other
                services provided by Pharmaspray to Medtech;
                and

            

    

    

    
      	
              G.  

            	
              This
                Agreement
                supersedes, amends and replaces an agreement between Pharmaspray
                B.V. and
                Wartner U.S.A. B.V. dated December 18, 2003 including any and all
                schedules and annexes thereto, and the amended and restated Logistics
                Agreement between the same parties dated March 2,
                2006.

            

    

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    NOW
      THEREFORE THE PARTIES AGREE AS FOLLOWS:

    

    
      	
              1.  

            	
              Definitions

            

    

    

    
      	
              1.1.  

            	
              The
                term “Acceptance
                of the Materials” shall mean the point in time at which the Materials (as
                defined hereafter) are physically handed over to or become under
                the
                control and care of Pharmaspray in order to manufacture and package
                the
                Products.

            

    

    

    
      	
              1.2.  

            	
              The
                term “Agreement”
                shall mean this document including the Quality Manual and all (further)
                Schedules and annexes hereto and thereto, each as amended from time
                to
                time by the Parties upon mutual written
                agreement.

            

    

    

    
      	
              1.3.  

            	
              The
                term
                “Commencement Date” shall mean September 21,
                2006.

            

    

    

    
      	
              1.4.  

            	
              The
                term "Delivery
                of the Products" shall mean the point in time at which the Products
                (as
                defined hereafter) are delivered to Medtech or the designated agent
                or
                distributor of Medtech. Unless otherwise specified in writing, Delivery
                of
                Products shall occur ex works (EXW, incoterms 2000) in
                Veendam.

            

    

    

    
      	
              1.5.  

            	
              The
                Term “Force
                Majeure” shall mean those circumstances which are unforeseeable and beyond
                the reasonable control of each of the Parties and which prevent the
                total
                or partial carrying out of any obligation by a party under this Agreement,
                such as acts or regulations or decrees of any government (de facto
                or de
                jure), natural phenomena, such as earthquakes and floods, fires,
                riots,
                shipwrecks, freight embargoes or other circumstances whether similar
                or
                dissimilar to those enumerated
                above.

            

    

    

    
      	
              1.6.  

            	
              The
                term
                “Intellectual Property Rights” shall mean any and all intellectual
                property rights, good will, know-how and other intangibles relating
                to the
                Product and its packaging including (but not limited to) national
                and
                international patents, trade name(s) and
                trademark(s).

            

    

    

    
      	
              1.7.  

            	
               The
                term
                “Logistic Services” shall mean all services provided by Pharmaspray as
                from the beginning of the manufacture of the Product until the physical
                delivery of the Product to Medtech, Medtech's distributors, agents
                or
                other destinations, including the storage and the arranging of
                transport.

            

    

    

    
      	
              1.8.  

            	
              The
                term "Machine"
                shall mean only the shrink-wrap module acquired by Pharmaspray on
                or about
                January 24th, 2007 for the packaging of the Product, as specified
                in
                Schedule 3. This Machine is specially equipped for USA packaging
                with a
                turn, stack, collate and foil-wrap module and headers for top & bottom
                quality seals.

            

    

    

    
      	
              1.9.  

            	
              The
                term “Materials”
                shall mean all semi fabrics, ingredients, spare parts, and packaging
                material necessary to assemble the
                Product.

            

    

    

    
      	
              1.10.  

            	
              The
                term “Packaging
                Services” shall mean the packaging of the Product(s) (as defined
                hereafter) by Pharmaspray according
                to the
                Quality Manual (as defined hereafter) and other specific
                instructions of Medtech.

            

    

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	
              1.11.  

            	
              The
                term
                “Procurement Services” shall mean the various acts of identifying,
                qualifying, ordering and obtaining via Purchase Orders or other means
                those Materials necessary or appropriate to the production of Products
                until such Materials are physically delivered to Pharmaspray. In
                performing Procurement Services, Pharmaspray shall act for its own
                account
                and not as agent for Medtech.

            

    

    

    
      	
              1.12.  

            	
              The
                term “Product”
                shall mean a consumer product composed and/or manufactured on behalf
                of
                Medtech bearing the Wartner® or other trademarks owned by Medtech and used
                for the cryogenic treatment of warts, skin tags or other lesions
                in
                humans, according to Medtech’s specifications as described in Schedule
                1.

            

    

    

    
      	
              1.13.  

            	
              The
                term “Production
                Services” shall mean the manufacture of the Product, including production,
                assembly, filling and labelling of the aerosol cans by Pharmaspray
                as
                instructed by Medtech in accordance with the terms of this Agreement
                and
                the Quality Manual.

            

    

    

    
      	
              1.14.  

            	
              The
                term “Purchase
                Order” shall mean a written instruction to provide the Procurement
                Services, Production Services, Packaging Services and Logistics Services,
                which instruction is prepared by Medtech and directed to Pharmaspray
                and
                includes specific instruction as to the delivery of the
                Product.

            

    

    

    
      	
              1.15.  

            	
              The
                term “Quality
                Manual” shall mean the Quality Agreement attached hereto as Schedule 5, as
                it may be subsequently amended, revised or replaced upon mutual written
                agreement.

            

    

    

    
      	
              1.16.  

            	
              The
                term “Schedule”
                shall mean any schedule to this Agreement, including any amendment
                thereto. 

            

    

    

    
      	
              1.17.  

            	
               The
                term
                “Storage Location” shall mean the warehouse located at Demeterlaan 30 and
                Cereslaan 9 (9641 ML) Veendam unless otherwise agreed by the Parties
                in
                writing. 

            

    

    

    
      	
              1.18.  

            	
              The
                term “Supplier”
                shall mean suppliers designated or appointed by Pharmaspray, subject
                to
                approval by Medtech, as described – non limitative – in Schedule
                2.

            

    

    

    
      	
              1.19.  

            	
              The
                term “Turn-Key
                Agreement” shall mean an understanding between the Parties acknowledging
                the assumption of all responsibility by Pharmaspray for
                all  Procurement Services, Production Services, Packaging
                Services, Logistics Services and other services necessary or appropriate
                to the fulfilment of Purchase Orders for the Product except as otherwise
                provided in this Agreement.

            

    

    

    
      	
               

            	
              In
                as far as
                applicable in the context of the Agreement, terms defined in the
                singular
                shall include the plural and vice versa.

            

    

    

    
      	
              2.  

            	
              Procurement,
                Production, Packaging and Logistic
                Services

            

    

    

    
      	
              2.1.  

            	
              On
                the terms and
                conditions of the Agreement, Medtech hereby appoints Pharmaspray
                and
                Pharmaspray hereby accepts such appointment to provide the Procurement
                Services, Production Services, Packaging Services and the Logistic
                

            

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	 	Services
              during the
              term of the Agreement in a manner befitting a careful contractor,
              excepting only as provided herein.
	 	 
	
              2.2.  

            	
              Without
                limiting the
                (general) obligations of the contracting Parties under this Agreement,
                the
                Parties shall provide mutual assistance and shall co-operate with
                each
                other and with third parties in order to ensure that the quality
                of the
                Procurement, Production, Packaging and Logistics Services are maintained
                and that the Parties' expectations in entering into this Agreement
                are
                fulfilled; in particular, Pharmaspray represents that it has such
                resources necessary to fulfil its obligations and that it shall be
                pro-active in resolving any problems. Medtech shall promptly inform
                Pharmaspray of all changes in its Wartner® business which may impact on
                the performance of the Production Services under this
                Agreement.

            

    

    

    
      	
              2.3.  

            	
              Pharmaspray
                shall
                provide the Procurement services, Production Services, Packaging
                Services
                and Logistics Services in accordance with the applicable ISO standards,
                the Quality Manual and Schedules, any (other) specific instructions
                of
                Medtech and any further mandatory national and international
                specifications, as applicable from time to
                time.

            

    

    

    
      	
              2.4.  

            	
              Medtech
                will provide
                Pharmaspray every month with a twelve month rolling sales forecast
                for the
                Products. The forecast for the three month period immediately following
                the issuance of the forecast shall be converted into Purchase Orders
                from
                Medtech to Pharmaspray, which Purchase Orders shall be deemed
                binding.

            

    

    

    
      	
              2.5.  

            	
              If
                Pharmaspray
                incurs costs directly based upon Medtech’s forecast for the next three
                months, and Medtech does not issue a Purchase Order related to those
                costs
                within six months after the applicable month, Pharmaspray may charge
                such
                costs to Medtech.

            

    

    

    
      	
              2.6.  

            	
              Pharmaspray
                will
                source the Materials mentioned in Schedule 2 from Suppliers approved
                by
                Medtech. Pharmaspray will manage a minimum amount of safety stock,
                with
                the minimum amount to be determined by the Parties.  To the
                extent any safety stock agreed by the Parties and maintained by
                Pharmaspray becomes obsolete due solely to the actions of Medtech,
                Medtech
                shall be obligated to reimburse Pharmaspray for its actual cost to
                purchase such safety stock.

            

    

    

    
      	
              2.7.  

            	
              Pharmaspray
                is
                responsible for the delivery of the Materials required for the manufacture
                or production of the Product to Pharmaspray's
                premises.  Notwithstanding the foregoing, the parties recognize
                and agree that the procurement of the existing caps as set forth
                on
                Schedule 6 from Keltec Dispensing Systems, B.V. is a matter which
                is and
                will be the subject of a separate negotiation and multi-party agreement,
                which may or may not conform to the terms of this
                Agreement.

            

    

    

    
      	
              2.8.  

            	
              Subject
                to clause
                7.3 and 7.5 and the provisions of Section 9, Pharmaspray is responsible
                for the compliance of the Materials with the applicable ISO standards
                and
                any further national and international specifications applicable
                from time
                to time at the moment of Acceptance of the Materials. Pharmaspray
                shall
                check such compliance, in as far as visually observable, at the Acceptance
                of the Materials.

            

    

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	
              2.9.  

            	
              Pharmaspray
                shall
                deliver the Products related to a specific written order of Medtech
                to the
                distributors or agents of Medtech within four (4) weeks upon such
                order,
                provided that Pharmaspray has received the sales forecast the specific
                order is based upon, in due time.

            

    

    

    
      	
              2.10.  

            	
              Medtech
                is allowed
                to conduct regularly scheduled quality audits of both the production
                process and the Product at Pharmaspray’s premises at any reasonable time
                after receipt of written notice from Medtech of its intent in advance.
                Pharmaspray may require its representative to be present and that
                such
                visit is under the condition that the internal rules of Pharmaspray
                or the
                Storage Location are being complied with. Medtech will be responsible
                for
                all associated costs of such quality audits. Medtech shall have the
                right
                to reject Products that do not meet the Product Specifications set
                forth
                in Schedule 1, the Quality Manual or other specific instructions
                of
                Medtech. Reasonable efforts will be made to salvage usable portions
                of any
                batch should a sampling of Products not be in compliance with the
                Product
                Specifications set forth in Schedule 1, the Quality Manual or other
                specific instructions of Medtech.

            

    

    

    
      	
              2.11.  

            	
              Pharmaspray
                shall
                provide Medtech with updates on its business operations as specified
                in
                the Quality Manual.

            

    

    

    
      	
              2.12.  

            	
              Pharmaspray
                shall
                keep an adequate administration of deliveries to Medtech’s distributors or
                agents. Pharmaspray shall provide copies of all shipping documents
                to
                Medtech in case of re-calls, whatever the cause for such re-calls
                may
                be.

            

    

    

    
      	
              2.13.  

            	
              Each
                Party shall,
                upon execution of this Agreement, appoint one of its employees to
                be a
                relationship manager responsible for liaison between the
                Parties.  The relationship managers shall conference not less
                than quarterly and meet in person not less than annually to coordinate
                the
                production activities, handle purchase orders, track assembly progress
                and
                any packaging work, movement of Product, deliveries, sales status
                and the
                current status of the business relationship and manage issues that
                have
                arisen.

            

    

     

    
      	
              2.14.  

            	
              Conveyance
                and
                delivery of the Products shall occur ex works (EXW) in Veendam, unless
                otherwise agreed between the Parties in
                writing.

            

    

     

    
      	
              2.15.  

            	
              Medtech
                is and shall
                at all times remain the owner of the Intellectual Property Rights
                to the
                Product in the United States, Canada and certain other countries
                where it
                has Intellectual Property Rights. No license of whatever nature in
                relation to any Intellectual Property Rights is granted by Medtech
                to
                Pharmaspray.  Pharmaspray shall have the obligation to obtain
                and maintain all governmental licenses, permits or approvals necessary
                to
                manufacture the Product at its facility in
                Veendam.

            

    

     

    
      	
              3.  

            	
              Packaging

            

    

    

    
      	
              3.1.  

            	
              Pharmaspray
                will
                package the Product according to the Quality Manual and other specific
                instructions of Medtech.

            

    

    

    
      	
              3.2.  

            	
              Pharmaspray
                has
                acquired the Machine as described in clause 1.8 above, directly from
                Alloga. The acquirement costs were and will be borne by
                Pharmaspray.

            

    

    

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	
              4.  

            	
              Transport

            

    

    

    
      	
              4.1.  

            	
              Medtech
                is
                responsible for transport of delivered Products from the premises
                of
                Pharmaspray at Veendam to her distributors, agents or (other) final
                destinations. The Parties agree that Pharmaspray shall organize this
                transport under the authority of and on expense of Medtech, thus
                acting as
                representative of Medtech.

            

    

    

    
      	
              4.2.  

            	
              Medtech
                shall
                designate the carrier(s)/transporter(s) to be involved in transportation
                of delivered Products. Pharmaspray, as representative of Medtech,
                will
                contract these carriers/transporters; Medtech being the contractant
                of the
                carrier/transporter.

            

    

    

    
      	
              4.3.  

            	
              All
                costs of
                transport taking place after delivery, charged to Pharmaspray, will
                be
                charged on to Medtech. Pharmaspray will provide Medtech with copies
                of the
                transport invoices the on-charging is based
                upon.

            

    

    

    
      	
              4.4.  

            	
              After
                delivery (ex
                works) of the Products has taken place, Pharmaspray is neither responsible
                nor liable for the acts and omissions of carriers/transporters that
                are
                contracted by Pharmaspray on behalf of
                Medtech.

            

    

    

    
      	 	Loading,
              stowage and
              discharging
	 	 
	
              4.5.  

            	
              The
                obligation of
                (un)loading, stowage and discharging the Materials and/or the Products
                and
                the liability for any damage to and/or loss of the Materials and/or
                Products caused by (un)loading, stowage and/or discharging the Materials
                and/or the Products rests with Pharmaspray, until delivery of the
                Products
                to Medtech defined in clause 2.14.

            

    

    

    
      	
              4.6.  

            	
              Any
                stipulation,
                condition, reservation or exemption as to responsibility and/or liability
                of Pharmaspray for loss of and/or damage to the Materials and/or
                the
                Products, occurring during loading on, stowing, and subsequently
                to the
                discharging from the means of carriage in which the Materials and/or
                the
                Products are (to be) carried (before delivery to Medtech), shall
                be null
                and void unless with prior written consent of
                Medtech.

            

    

    

    
      	
              4.7.  

            	
              Pharmaspray
                shall at
                all times load, stow and discharge the Materials and the Products
                in
                accordance with the applicable provisions of the Quality Manual and
                the
                specific instructions of Medtech.

            

    

    

    
      	
              5.  

            	
              Independent
                and other Subcontractors of
                Pharmaspray

            

    

    

    
      	
              5.1.  

            	
              Pharmaspray
                is
                entitled to contract and instruct (independent) subcontractors and/or
                auxiliary persons for the manufacturing, packaging, and storage of
                the
                Product, subject to the reasonable written consent of Medtech and
                subject
                to reasonable assurance that all confidential and proprietary information
                of Medtech will be safeguarded.

            

    

    

    
      	
              5.2.  

            	
              Pharmaspray
                shall be
                responsible and liable for the acts and omissions of its employees,
                servants, (independent) subcontractors, agents, suppliers and 
                other

            

    

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
    

    
      	 	
              persons
                whose services it uses for the performance of its obligations under
                this
                Agreement, as if such acts and omissions were its own, cases of Force
                Majeure excepted.

            

    

    
      	 	 
	
              6.  

            	
              Rates,
                Charges and Payment Terms

            

    

    

    
      	
              6.1.  

            	
              All
                rates, costs and
                expenses with respect to the production and packaging and storage
                services
                shall be charged and invoiced by Pharmaspray to Medtech on a weekly
                basis
                and in conformity with the provisions set down in Schedule 4 regarding
                the
                rates and charges. The prices set out on Schedule 4 shall be fixed
                prices
                for the term of this Agreement; provided, however, Pharmaspray shall
                be
                entitled to pass on to Medtech in the first quarter of each calendar
                year,
                by mutual written agreement, any significant net increase in prices
                charged by third parties in connection with Pharmaspray's services
                provided (including any increase in prices for raw
                materials).  In the event of a demonstrable price-increase of
                one or more Materials exceeding 5%, Pharmaspray shall also during
                the
                calendar year be entitled to pass on to Medtech this price-increase
                in
                consultation with Medtech.

            

    

    

    
      	
              6.2.  

            	
              Invoices
                shall be
                issued and expressed in Euros and payment shall be made in Euros
                to a
                Dutch bank account of Pharmaspray. If, at the request of Pharmaspray,
                any
                costs, duties and the like involved with payment shall be paid by
                Medtech
                in another currency and/or a foreign bank account, the costs for
                such
                payment shall be borne by
                Pharmaspray.

            

    

    

    
      	
              6.3.  

            	
              Any
                objections to
                the invoice Medtech has received from Pharmaspray shall be made by
                Medtech
                in writing within sixty (60) days from the invoice date. If no objections
                are made within 60 days from the invoice date, the invoice shall
                be
                binding on both Parties.

            

    

    

    
      	
              6.4.  

            	
              Medtech
                shall pay
                the invoiced amounts within sixty (60) days counting from the invoice
                date. Medtech shall only be allowed to pay at a later date with prior
                written consent of Pharmaspray.  If Medtech pays the invoice
                within eight (8) days of the invoice date, Medtech shall be entitled
                to
                receive a credit equal to 3% of the total amount of the invoice,
                except of
                the costs of transport organized on behalf of Medtech as mentioned
                in
                clause 4.3.

            

    

    

    
      	
              6.5.  

            	
              Any
                payment to be
                made by either Party under this Agreement shall be made in full without
                set-off, restriction, condition or deduction for or on account in
                any
                counterclaim.

            

    

    

    
      	
              6.6.  

            	
              Any
                and all
                outstanding payments of Medtech due to Pharmaspray shall become
                immediately payable (opeisbaar)
                if Medtech is declared bankrupt or in moratorium of payments, discontinues
                its business or if its business is
                liquidated.

            

    

    

    
      	
              6.7.  

            	
              If
                Medtech does not
                pay the amount due within the agreed time, Medtech shall be legally
                held
                to be in default and shall be liable to pay interest equal to the
                Dutch
                statutory interest rate plus 4% over the entire invoice amount, commencing
                on the due date of the invoice, until the actual date of payment.
                Medtech
                is liable to pay any and all judicial and/or extra-judicial costs
                for debt
                collection by Pharmaspray.

            

    

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	
              6.8.  

            	
              To
                the extent that
                Product produced and delivered by Pharmaspray are for sale and use
                in the
                United States, Canada or anywhere else outside The Netherlands, no
                VAT tax
                shall be included in the invoice.

            

    

    

    
      	
              6.9.  

            	
              The
                Parties agree
                that the prices, rates and charges appearing in Schedule 4 have been
                established for purposes of this Agreement with mutual implicit
                assumptions in cost of goods sold (“COGS”) and exchange rates between the
                U.S. dollar and the Euro. To the extent that fluctuations in exchange
                rates occur such that there is a variance of more than 10% in any
                twelve
                month period in the effective exchange rate, the Parties agree to
                meet and
                to negotiate in good faith to achieve an equitable and commercially
                viable
                accommodation. Increases in COGS not primarily related to exchange
                rates
                shall be subject to annual review, and to the extent reasonably applicable
                shall be modulated by published cost-of-living
                indexes.

            

    

    

    
      	
              7.  

            	
              Warranties

            

    

    

    
      	
              7.1.  

            	
              Subject
                to clause
                7.3 and 7.5, Pharmaspray represents and warrants that the performance
                of
                the Production Services shall be in compliance with the Product
                Specifications set forth in Schedule 1, the Quality Manual and any
                other
                provisions of this Agreement, cases of Force Majeure
                excepted.

            

    

    

    
      	
              7.2.  

            	
              Subject
                to clauses
                7.3 and 7.5, Pharmaspray represents and warrants that she, after
                delivery
                of the Machine as mentioned in clause 3.2 to Pharmaspray, shall assemble
                the Products in complete and correct state and in compliance with
                the
                Product Specifications set forth in schedule 1, the Quality Manual
                and any
                other provisions of this Agreement, cases of Force Majeure
                excepted.

            

    

    

    
      	
              7.3.  

            	
              The
                representation
                and warranty mentioned in clause 7.1 and 7.2 do not apply to defects
                in
                the Product caused by defects in Materials delivered to Pharmaspray
                by  Suppliers if the Materials are accompanied by a certificate
                of analysis conforming with the Specifications and all approval procedures
                and criteria required by the Quality Manual are met. The representation
                and warranty does not apply to texts/artwork edited or provided by
                Medtech.

            

    

    

    
      	
              7.4.  

            	
              The
                Parties
                represent and warrant that, during this Agreement and after termination
                and completion of this Agreement, except as may be required by judicial
                process or the regulatory requirements of governmental authority
                having
                jurisdiction over the Parties and/or Products, they shall keep
                confidential any information whatsoever regarding the Materials,
                the
                Products, the contents of this Agreement, and the Quality Manual
                and
                Schedules and not provide any third party with such confidential
                information unless with prior written consent of the other
                Party.

            

    

    

    
      	
              7.5.  

            	
              The
                Parties agree
                that the existing design of the Product, and specifically the existing
                cap
                provided by Keltec which is set forth in Schedule 6, are the
                responsibility of Medtech as specification holder. The responsibility
                of
                Pharmaspray is to insure that production of the Product including
                the
                existing Keltec cap is in all respects in

            

    

    
 

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      
        	 	
                conformance
                  with specifications and applicable regulatory
                  requirements. The warranties of Pharmaspray shall be viewed in
                  all
                  respects as limited by this Section
                  7.5.

              

      

    

      

    
      	8.    
                  	Insurance
	 	 
	
              8.1  

            	
              Both
                Parties shall
                on request provide the other Party with periodic evidence of satisfactory
                product liability insurance coverage for the
                Products.

            

    

    

    
      	
              9.

            	
              Liability
                

            

    

    

    
      	
              9.1.

            	
              Pharmaspray
                shall be
                liable for any and all damages and costs suffered by Medtech as a
                consequence of Pharmaspray’s non-performance (“tekortkoming
                in de nakoming”) of its obligations under the Agreement, including
                but not limited to the warranties granted by Pharmaspray pursuant
                to
                clause 7.1 and 7.2 of this Agreement, cases of Force Majeure excepted.
                

            

    

    

    
      	
              9.2.

            	
              Except
                as set forth
                in Section 7.5, Pharmaspray shall be responsible for damage, defects,
                non-delivery or late delivery caused by Materials from Suppliers.
                Notwithstanding the foregoing, Pharmaspray is not liable for damage,
                defects, non-delivery or late delivery caused by the design of the
                Product, the formula(s), the package or instructions, prescribed
                by
                Medtech and/or shortcomings caused by Medtech.

            

    

    

    
      	
              9.3.

            	
              As
                to arranging for
                transport of Products on behalf of Medtech after delivery ex works
                has
                taken place, Pharmaspray is only liable for her own acts and omissions;
                Pharmaspray is not to be considered the insurance carrier or shipper.
                

            

    

    

    
      	
              9.4.

            	
              The
                Parties agree
                that Pharmaspray’s liability is in any case limited to the greater of (1)
                the invoiced value of the Products for that specific order; or (2)
                the
                maximum amount Pharmaspray’s insurance company will compensate for in that
                particular case provided that Pharmaspray has arranged and maintained
                for
                sufficient insurance coverage or could reasonably expected to arrange
                for,
                and maintain a certain level of insurance coverage, considering the
                standard practice in the industry, in accordance with this Agreement.
                

            

    

    

    
      	
              9.5.

            	
              Only
                Medtech shall
                be responsible and liable for the content of artwork, consumer
                instructions and label copy. Pharmaspray is not responsible or liable
                for
                the content of consumer instructions, artwork and label copies and
                any
                (other) texts on the Products, including the Product package. Pharmaspray
                shall only be responsible for assuring that only artwork provided
                by or
                approved by Medtech is accurately utilized.

            

    

    

    
      	
              9.6.

            	
              Medtech
                shall be
                liable for any and all material damages and costs suffered by Pharmaspray
                as a consequence of a defect (or defects) in Materials delivered
                by
                Medtech or defect(s) in texts/artwork edited or provided by Medtech.
                

            

    

    

    
      	
              9.7.

            	
              Neither
                of the
                Parties shall be liable in case of Force Majeure.
                

            

    

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	
              9.8.

            	
              Claims
                of either
                party against the other expire in accordance with the provisions
                of the
                Dutch Civil Code. Shorter expiration dates are not valid, unless
                with
                prior written consent of the other Party.

            

    

     

    
      	10.	Indemnifications
	 	 
	
              10.1.

            	
              Subject
                to the
                provisions of Sections 7.3, 7.5 and 9, Pharmaspray will hold harmless
                and
                indemnify Medtech from and in regard to any and all claims by third
                parties in connection to the performance by Pharmaspray of the production
                and packaging services such as, but not limited to, claims originating
                from defectiveness of the Products and/or the Materials required
                for the
                Products and the production process, cases of Force Majeure excepted.
                

            

    

    

    
      	
              10.2.

            	
              Medtech
                will hold
                harmless and indemnify Pharmaspray from and in regard to any and
                all
                claims by third parties other than Suppliers, originating from
                

            

    

    

    
      	 	
              1.

            	
              defects
                in the
                texts/artwork edited, approved or provided by Medtech, or
                

            

    

    

    
      	 	
              2.

            	
              the
                design of the
                Product, formula(s), component parts packaging or instructions provided,
                prescribed or designed by Medtech or Medtech's predecessors in interest.
                

            

    

     

    
      	11.	Exclusivity
	 	 
	
              11.1.

            	
              During
                the term of
                this Agreement, Pharmaspray shall not provide any services whatsoever
                to
                third parties in relation to aerosol products similar to or in any
                way
                competing with the Product in the United States, Canada and Mexico.
                

            

    

    

    
      	
              11.2.

            	
              During
                the term of
                this Agreement, Medtech shall purchase the Product only and exclusively
                from Pharmaspray. 

            

    

     

    
      	12. 	Duration
              and
              Termination
	 	 
	
              12.1.

            	
              This
                Agreement shall
                become effective for an initial period of three years, starting from
                the
                Commencement Date. This Agreement may be renewed for additional three
                year
                periods upon the mutual written consent of the Parties no later than
                six
                months prior to the then applicable expiration date.
                

            

    

     

    
      	
              12.2.

            	
              Each
                of the Parties
                has the right to terminate this Agreement with immediate effect by
                giving
                written notice if any of the following events shall occur:
                

            

    

    

    
      	
               

            	
              a.

            	
              the
                other party
                breaches any of the terms of this Agreement and fails to remedy such
                breach within thirty (30) days after written notice requiring to
                do so,
                unless such breach or failure does not justify this with its consequences
                in view of its minor importance; 

            

    

    
      	 	
              b.

            	
              the
                other party
                files a petition for moratorium of payments with the competent court
                or is
                granted a moratorium of payments; 

            

    

    
      	 	
              c.

            	
              the
                other party
                files a petition for bankruptcy with the competent court or is
                

            

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	 	 	declared
              bankrupt;
              or 
	 	
              d.

            	
              the
                board of
                directors of the other party resolves to dissolve or liquidate its
                company. 

            

    

    

    
      	
              12.3.

            	
              In
                case of
                termination of the Agreement pursuant to Clause 12.2, the terminating
                Party is entitled to receive full compensation for any and all direct
                damage suffered by it as a result of the termination and/or, in the
                case
                of the event stated under Clause 12.2 sub a., any damage suffered
                as a
                result of such breach. 

            

    

    

    
      	
              12.4.

            	
              In
                deviation of
                Clause 12.1, Medtech may terminate this Agreement with immediate
                effect by
                giving written notice, without any compensation or damages whatsoever
                to
                Pharmaspray, if Pharmaspray becomes owned or controlled by or associates
                with or merges with a producer who provides production services to
                competitors of the Product. 

            

    

     

    
      	13.	Completion
              after
              termination
	 	 
	
              13.1.

            	
              Upon
                termination of
                the Agreement, Medtech is obliged to take delivery of the Materials
                and
                (semi) Products still in the possession and/or under the control
                of
                Pharmaspray on the expiration date of the Agreement or, in case of
                termination with immediate effect, within 2 weeks upon such termination,
                after payment of all outstanding amounts to Pharmaspray. Pharmaspray
                and
                Medtech shall mutually agree as to the allocation of costs incurred
                for
                raw materials, labels and packaging; provided, that, in the event
                Medtech
                terminates this Agreement for any reason other than as set forth
                in
                Sections 12.2 and 12.4 hereof, Medtech shall be obligated to purchase
                from
                Pharmaspray, at Pharmaspray’s actual cost, any safety stock agreed between
                Medtech and Pharmaspray; and provided further, that, notwithstanding
                the
                foregoing, any breaching Party shall be fully responsible for such
                costs
                (including, without limitation, safety stock maintained by
                Pharmaspray).  Medtech shall have the right, but not the
                obligation, to purchase any finished Products being held in Pharmaspray’s
                inventory for which no Purchase Orders have been submitted.
                

            

    

    

    
      	
              13.2.

            	
              If
                Medtech
                terminates this Agreement within 5 years of the original date of
                acquisition of the Machine, Medtech shall, at the sole discretion
                of
                Pharmaspray, acquire the Machine from Pharmaspray for an amount equal
                to
                the following percentages of Pharmaspray's acquisition cost of the
                Machine: 

            

    

     

    
      
        	 	 During
                year 1: 	75%
	 	 During
                year 2:	60%
	 	 During
                year 3:	40%
	 	 During
                year 4:	25%
	 	 During
                year 5:	10%

      

    

      

    
      
        	 	
                The
                  acquisition cost of the machine is stipulated and agreed to be
€
                  111.335,20. The original date of acquisition of the Machine for
                  purposes
                  of this Agreement is January 24, 2007. Should the machine be utilized
                  by
                  Pharmaspray for purposes other than the manufacture of the Product
                  hereunder, the acquisition cost to Medtech shall be
                  

              

      

    

     

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
    

    
      	 	reduced
              proportionately to the additional
              use.

    

    

    
      	14.	No
              Rescission
	 	 
	
              14.1

            	
              The
                Parties herewith
                expressly waive the right to rescind the Agreement pursuant to Article
                265
                of Book 6, Dutch Civil Code. 

            

    

     

    
      	15.	Miscellaneous
	 	 
	
              15.1.

            	
              Changes
                in the Quality Manual. Subject to the written consent of
                Pharmaspray which shall not be unreasonably withheld, delayed or
                conditioned, Medtech reserves the right to amend or adapt the Quality
                Manual and Schedules to changes in the aforementioned regulation
                and
                legislation and / or to the introduction of new regulations and /
                or
                legislation regarding the quality requirements of the Product from
                time to
                time. 

            

    

    

    
      	
              15.2.

            	
              Successors
                and Assignments. This Agreement is binding on and for the benefit
                of both Parties and their successors and permitted assignees. Neither
                Party may assign (its rights under) this Agreement without the prior
                written consent of the other party. Pharmaspray shall have no rights
                in
                the Materials and / or Products of Medtech and may not and shall
                not
                attempt to assign any interests, either real or presumed, to the
                Materials
                and /or (Semi) Products of Medtech.

            

    

    

    
      	
              15.3.

            	
              Entire
                Agreement. This Agreement represents the entire agreement of the
                Parties with respect to its subject matter, and supersedes all prior
                proposals, agreements, memoranda and / or understandings with respect
                to
                this Agreement or its subject matter between Medtech and Wartner
                USA B.V.
                and Pharmaspray B.V. Any future representation, agreement, understanding
                or waiver will only be binding if in writing and signed by the Party
                sought to be bound. 

            

    

    

    
      	
              15.4.

            	
              Schedules
                and Annexes. Each schedule, annex and / or the applicable
                provisions of the Quality Manual will become part of and subject
                to this
                Agreement upon signature and date by both Parties.
                

            

    

    

    
      	
              15.5.

            	
              Waivers.
                Either Party’s failure strictly to enforce any provision of this Agreement
                will not be construed as a waiver of that provision or as excusing
                the
                other Party from future performance.

            

    

    

    
      	
              15.6.

            	
              Notices.
                All notices required or permitted under this Agreement shall be in
                writing
                unless otherwise indicated in this Agreement. The notifying Party
                shall
                send the written notice to the address of the other Party as shown
                at the
                beginning of this Agreement and/or any other address as agreed upon
                by the
                receiving Party. Sent notices will only be effective upon actual
                receipt
                by the other Party. 

            

    

    

    
      	
              15.7.

            	
              Electronic
                Mail. The Parties agree that day-to-day communication can also
                be
                by electronic mail (e-mail). Sent e-mail messages will only be effective
                upon actual receipt by the other Party. Notwithstanding the preceding
                passages, any message, notice and /or document relating to modification
                and/or which affects the effect of this Agreement shall only have
                binding
                effect if in writing (not being electronic mail and/or other electronic
                documents) and with written consent of the Parties.
                

            

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	
              15.8.

            	
              Confidentiality.
                Each Party shall, during this Agreement and after termination and
                completion of this Agreement, keep confidential any information whatsoever
                regarding the business of the other Party and not provide any third
                party
                with such confidential information unless with prior written consent
                of
                the other Party, except as may be reasonably required by judicial
                process
                or compliance with applicable governmental and regulatory requirements.
                

            

    

    

    
      	
              15.9.

            	
              Mandatory
                Law. This Agreement shall only take effect to the extent that
                its
                provisions are not contrary to any provision of mandatory (national
                and /
                or international) law. Any provision of this Agreement being contrary
                to
                any provision of mandatory law or otherwise being null and void does
                not
                effect the validity of the other provisions of this Agreement.
                

            

    

    

    
      	
              15.10.

            	
              General
                Terms and Conditions. The applicability of any general terms and
                conditions of the contracting Parties, other than those which are
                expressly and with written consent of both Parties declared applicable
                to
                the relationship between Medtech and Pharmaspray under this Agreement,
                is
                hereby expressly excluded. 

            

    

    

    
      	
              15.11.

            	
              Changes
                to the Agreement. Provisions that deviate from this Agreement can
                be invoked by both Parties only if and to the extent that these provisions
                are accepted by both Parties in writing.

            

    

    

    
      	
              15.12.

            	
              Severability.
                If any term or condition of this Agreement is null and void or will
                become
                null and void during the course of this Agreement, the validity and
                effectiveness of all other terms and conditions shall not be impaired
                thereby. All terms and conditions of this Agreement are separable.
                

            

    

     

    
      	16.	Applicable
              law and
              jurisdiction
	 	 
	
              16.1.

            	
              This
                Agreement is
                exclusively governed and construed by Dutch law, as will all disputes
                that
                may arise from this Agreement. All legal concepts to which reference
                is
                made in this Agreement are Dutch legal concepts.
                

            

    

    

    
      	
               

            	
              All
                disputes,
                arising in connection with the present Agreement or further contracts
                and
                / or agreements resulting here from, which cannot be settled amicably,
                shall be settled by the competent Court of Groningen, The Netherlands,
                notwithstanding higher appeals. 

            

    

    

    [Remainder
      of page
      intentionally left blank]

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    This
      agreement was signed with duplicate originals in Irvington, New York on December
      21, 2007.

    

     

     

    

    
      	 	/s/
              Peter J.
              Anderson	 	/s/
              Jos
              Schott	 
	 	
              Medtech
                Products Inc.

            	 	Pharmaspray
              B.V.	 
	 	By:  Peter
              J. Anderson	 	By:
              Jos Schott 	 
	 	Treasurer	 	Managing
              Director 	 
	 	 	 	 	 

    

    

    
    

    
    

    
    

    
    

    
      

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

      

    

    
      	 
	
              Schedules

            

    

     

    

    
      	Schedule
              1	Product
              Definitions and Specification
	Schedule
              2	Suppliers
              and Materials
	Schedule
              3 	Packaging
Machine
              Specification
	Schedule
              4 	Prices,
              Rates and Charges
	Schedule
              5	Quality
              Manual
	Schedule
              6	Existing
              Cap for the
              Product

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00136-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00136-of-00352.parquet"}]]